Events & Presentations

Add Files Arbutus Biopharma Corporate Overview 832.2 KB	Add Files Arbutus Biopharma Corporate Overview 832.2 KB

Archived Events

Summary Toggle Jun 20,2019 10:00 AM EDT	JMP Securities Life Sciences Conference Listen to webcast
Summary Toggle Jun 05,2019 3:00 PM EDT	Jefferies 2019 Healthcare Conference Listen to webcast
Summary Toggle May 21,2019 11:00 AM EDT	RBC Capital Markets Healthcare Conference Click here for webcast
Summary Toggle May 20,2019 1:00 PM EDT	UBS Global Healthcare Conference Click here for webcast
Summary Toggle May 06,2019 4:30 PM EDT	Arbutus Biopharma Corporation 2019 First Quarter Financial Results and Corporate Update Click here for webcast
Summary Toggle Mar 11,2019 2:50 PM EDT	Cowen and Company 39th Annual Healthcare Conference Listen to webcast
Summary Toggle Mar 07,2019 1:30 PM PST	Arbutus Biopharma Corporation Fourth Quarter and Year End 2018 Financial Results and Corporate Update Listen to webcast
Summary Toggle Nov 07,2018 4:30 PM EST	Arbutus Biopharma Corporation 2018 Third Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Oct 09,2018 2:45 PM EDT	Chardan 2nd Annual Genetic Medicines Conference Listen to webcast
Summary Toggle Oct 03 - 06,2018	International HBV Meeting Supporting Materials Mode of action studies on HBV RNA destabilizer AB-452 1.3 MB
Summary Toggle Sep 25,2018	Antivirals: Targeting HBV and Beyond Supporting Materials View Presentation 2.7 MB
Summary Toggle Sep 04,2018 9:50 AM EDT	B. Riley FBR Healthcare Conference
Summary Toggle Aug 15,2018 2:30 PM EDT	2018 Wedbush PacGrow Healthcare Conference Listen to webcast
Summary Toggle Aug 02,2018 4:30 PM EDT	Arbutus to Report Second Quarter 2018 Financial Results Listen to webcast
Summary Toggle Jul 10,2018 4:00 PM EDT	Roivant Pipeline Day Listen to webcast
Summary Toggle May 03,2018 1:30 PM PDT	Arbutus Biopharma Corporation 2018 First Quarter Financial Results and Corporate Update Listen to webcast Additional Information Arbutus would like to correct a misspeak by Koert VandenEnden in this archived webcast. At 14:50, when Mr. VandenEnden said “Arbutus’ net loss for Q1 2018 was $15.7 million ($0.33 per common share),” he meant to say, “Arbutus’ net loss for Q1 2018 was $17.9 million ($0.36 per common share).
Summary Toggle Apr 12,2018	EASL 2018 Supporting Materials Durable inhibition of hepatitis B virus replication and antigenemia using subcutaneously administered siRNA agent AB-729 in preclinical models 1.5 MB Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection AB-506 a next generation HBV capsid inhibitor and AB-452 an HBV RNA destabilizer 1.3 MB
Summary Toggle Mar 14,2018 1:30 PM PDT	Arbutus Biopharma Corporation 2017 Fourth Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Dec 06,2017 3:00 PM PST	HepDART 2017 Supporting Materials A Next Generation HBV Capsid Inhibitor AB-506 In Vitro and In Vivo Antiviral Characterization (Poster) 10.1 MB A Next Generation HBV Capsid Inhibitor AB-506 In Vitro and In Vivo Antiviral Characterization (Presentation) 9.3 MB Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure 5 MB
Summary Toggle Oct 22,2017	AASLD 2017 Supporting Materials HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Viral 1.1 MB Pharmacokinetics and exploratory exposure-response of siRNAs administered monthly as ARB-001467 (ARB-1467) in a Phase 2a study i 468.4 KB Antiviral Characterization of a Next Generation Chemical Series of HBV Capsid Inhibitors In Vitro and In Vivo 9.1 MB Identification and Characterization of AB-452, a Potent Small Molecule HBV RNA Destabilizer In Vitro and In Vivo 1.4 MB In Vivo Study of a LNP siRNA Investigational Agent Applied Sequentially with Immunomodulatory Treatments for Chronic Hepatitis B 1.4 MB Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascen 790.3 KB Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAg Negative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper 1.3 MB
Summary Toggle Oct 10,2017	Chardan Inaugural Gene Therapy Conference
Summary Toggle Sep 25,2017	Discovery on Target: Targeting HBV Supporting Materials HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additivesynergistic effects in in vitro combination stud 2 MB RNA Interference: A New Tool in the Toolbox for Treatment of HBV 3 MB RNAi Based Human Therapy for Chronic Hepatitis B Infection 2.7 MB
Summary Toggle Sep 12,2017 1:00 PM EDT	LNP: Delivering mRNA Therapeutics to the Clinic Listen to webcast Supporting Materials View Presentation 5.1 MB
Summary Toggle May 24,2017	AGM Proxy Statement Additional Information IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, MAY 24, 2017 This Notice of the 2017 Annual General Meeting of Shareholders, the Management Proxy Circular and Proxy Statement, and our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2016 are available at http://investor.arbutusbio.com/financials.cfm
Summary Toggle May 22,2017	ICAR 2017 Supporting Materials Systematic In Vitro Evaluation of Current and Experimental Hepatitis B Therapeutics 335.5 KB Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B 1.6 MB
Summary Toggle Apr 22,2017	EASL 2017 Supporting Materials A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg Positive and HBeAg Negative Virally Suppressed Subjects with Hepatitis B 328.7 KB
Summary Toggle Dec 12,2016 1:30 PM PST	Arbutus Biopharma Corporation Conference Call Listen to webcast Supporting Materials View Presentation 754.3 KB
Summary Toggle Nov 11 - 14,2016	2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Supporting Materials Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection 1.5 MB Exploring Combination Therapy for Curing HBV 1.3 MB The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies 2.4 MB
Summary Toggle Sep 29,2016 2:00 PM PDT	Arbutus Biopharma HBV Product Pipeline Update Listen to webcast
Summary Toggle Jul 17 - 20,2016	2016 Controlled Release Society Conference Supporting Materials Advances in Clinically Viable LNP Compositions for mRNA Delivery 6.1 MB
Summary Toggle Jun 01 - 02,2016	5th Antiviral Drugs Research and Development Conference Supporting Materials Combination Therapy for Curing HBV 3.3 MB
Summary Toggle Apr 22,2016	11th Annual Drug Discovery Chemistry Conference Supporting Materials Combination Therapy for Curing HBV 3.9 MB
Summary Toggle Apr 14,2016	EASL 2016 Supporting Materials In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly 2.6 MB
Summary Toggle Nov 17,2015	AASLD Conference Supporting Materials Development of a Direct RNA Interference Therapy for Hepatitis Delta Virus Infection 1.2 MB TKM-HBV, a Novel RNA Interference Treatment for Chronic Hepatitis B, Rapidly Reduces Surface Antigen and other Viral Proteins in Both Intrahepatic and Peripheral Compartments 5.2 MB TKM-HBV, a Novel RNA Interference Treatment for Chronic Hepatitis B, has a Complementary Mode of Action to Current Standard of Care Nucleos(t)ide Analogs 1.9 MB

Events & Presentations

Presentations

Upcoming Events

Archived Events

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials